Key Clinical Questions
What are the most frequent types of antibiotic resistance?
Which patients are at risk for infections with antibiotic-resistant organisms?
How are antibiotic-resistant organisms transmitted among patients?
What types of genes confer antibiotic resistance?
What types of isolation precautions exist, and when are they indicated?
Antibiotic resistance was described at the dawn of the antibiotic era. In Alexander Fleming’s initial report of the antibacterial action of penicillin in 1929, he noted that it was usually inactive against enteric Gram-negative bacteria. In 1940, while engaged in isolating and purifying penicillin, Edward Abraham and Ernst Chain incidentally discovered that Escherichia coli produced penicillinase. While the global explosion and dissemination of antibiotic resistance in recent decades is alarming, perhaps it should not be too surprising. As most antibiotics are derived from substances produced by molds and bacteria to inhibit the growth of rival microorganisms, mechanisms of antibacterial resistance evolved before humans harnessed these compounds for medicinal use.
When antibiotics reduce populations of nonresistant organisms, resistant organisms are able to proliferate. Rates of invasive infections with drug-resistant bacteria increase after recent antibiotic exposure. Conversely, reduced use of antibiotics has been shown to decrease the prevalence of antibiotic-resistant organisms. Certain bacterial infections are now resistant to all antibiotics, with a limited number of promising antibiotics in the developmental pipeline.
Highly antibiotic-resistant organisms are usually thought of as exclusively hospital-acquired pathogens. However, community acquisition of resistant pathogens is on the rise, including methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase-producing E. coli. This chapter reviews resistant bacteria of importance to the hospitalist, including the ESKAPE pathogens, for which there may be no effective drug therapy in the near future (Table 185-1).
TABLE 185-1ESKAPE Pathogens: Multidrug-Resistant Bacteria Most Likely to have no Effective Drug Therapy in the Immediate Future |Favorite Table|Download (.pdf) TABLE 185-1 ESKAPE Pathogens: Multidrug-Resistant Bacteria Most Likely to have no Effective Drug Therapy in the Immediate Future
Enterococcus faecium (VRE)
Staphylococcus aureus (MRSA)
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)
The medically important staphylococci may be divided into two main groups based on the rapid coagulase test, a measure of the ability of a staphylococcal colony to produce a clot in a tube of rabbit serum. Coagulase-negative staphylococci (principally Staphylococcus epidermidis) have little virulence aside from biofilm production, and generally only cause infections of medical devices, such as central venous catheters and joint prostheses. By contrast, S. aureus (coagulase-positive) is innately pathogenic, and is one of the few bacteria that cause severe infection in both community and health care settings. An important exception to this rule is Staphylococcus lugdunensis, which despite being a coagulase-negative staphylococcus, clinically resembles S. aureus.